This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 24 °C Tuesday 2 June, 2020

Royalty gives up bid for Irish biotech firm Elan

The US intellectual property investor Royalty Pharma said that it received ‘repeated rejections’ from Elan.

Image: Julien Behal/PA Archive/Press Association Images

US INTELLECTUAL PROPERTY investor Royalty Pharma announced today it has abandoned its bid to take over Irish biotechnology company Elan after repeated rejections by Elan.

Royalty said its $7.9 billion offer had officially elapsed after Elan shareholders backed, by a thin margin, a share repurchase program which Royalty had opposed.

Royalty said it would not seek support from the Irish Takeover Panel to keep its offer alive in the wake of the vote.

“In light of recent developments, we are no longer pursuing the judicial review we had requested,” Pablo Legorreta, Royalty’s chief executive, said in a statement.

On June 10 Dublin-based Elan rejected as “wholly inadequate” Royalty’s latest bid for the company, aimed at getting access to income streams from its portfolio of drugs, including its blockbuster multiple-sclerosis drug Tysabri.

Four days later Elan’s board publicly authorizsed putting the company up for sale, inviting Royalty to participate.

“The Elan Board and management are aligned in maximising the full value potential of the business on behalf of its shareholders,” the company said in a June 14 statement.

- © AFP, 2013

Read: Elan’s Athlone unit to get $1bn in merger deal>

Read: Elan reports first operating profits for nine years>

  • Share on Facebook
  • Email this article

About the author:


Read next: